ch.oddb.org
 
Apotheken | Hôpital | Interactions | LiMA | Médecin | Médicaments | Services | T. de l'Autorisation
Information professionnelle sur Berinert® SC:CSL Behring AG
Information professionnelle complèteDDDAfficher les changementsimprimé 
Composit.Forme gal.Indic./emploiPosolog./mode d'empl.Contre-Ind.PrécautionsInteract.Grossesse
Apt.conduiteEffets indésir.SurdosagePropriétésPharm.cinét.Donn.précl.RemarquesNum. Swissmedic
PrésentationsTitulaireMise à jour 
B06AC01 - C1-Inhibitor, Plasma DerivedATC-DDD Version 2016. Source: WHO
B - Blood and Blood Forming Organs
 
B06 - Other Hematological Agents
 

No DDDs are established in this group.

B06A - Other Hematological Agents

This group includes preparations for local and systemic use, and also some preparations used for dissolving clots in catheters, hemodialysis clots etc.
See also:
V07A - All other non-therapeutic products
B01AB - Heparin group

B06AC - Drugs Used in Hereditary Angioedema
 

The DDD for lanadelumab is based on the starting dose.

B06AC01 - C1-Inhibitor, Plasma Derived
Concentr.Adm.RouteNote
 P 
2024 ©ywesee GmbH
Einstellungen | Aide | FAQ | Identification | Contact | Home